[go: up one dir, main page]

YU84603A - Novel tyrosine kinase inhibitors - Google Patents

Novel tyrosine kinase inhibitors

Info

Publication number
YU84603A
YU84603A YU84603A YUP84603A YU84603A YU 84603 A YU84603 A YU 84603A YU 84603 A YU84603 A YU 84603A YU P84603 A YUP84603 A YU P84603A YU 84603 A YU84603 A YU 84603A
Authority
YU
Yugoslavia
Prior art keywords
tyrosine kinase
kinase inhibitors
formula
novel tyrosine
compounds
Prior art date
Application number
YU84603A
Other languages
Serbo-Croatian (sh)
Inventor
Mark Wittman
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G. Saulnier
Peiying Liu
Xiaopeng Sang
David Frennesson
Karen Stoffan
James Tarrant
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of YU84603A publication Critical patent/YU84603A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
YU84603A 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors YU84603A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28

Publications (1)

Publication Number Publication Date
YU84603A true YU84603A (en) 2006-03-03

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
YU84603A YU84603A (en) 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors

Country Status (25)

Country Link
EP (1) EP1381598A4 (en)
JP (1) JP2004534010A (en)
KR (1) KR20030083016A (en)
CN (1) CN1514833A (en)
AR (1) AR035804A1 (en)
BG (1) BG108206A (en)
BR (1) BR0208373A (en)
CA (1) CA2442428A1 (en)
CZ (1) CZ20032615A3 (en)
EE (1) EE200300475A (en)
GE (1) GEP20053660B (en)
HR (1) HRP20030844A2 (en)
HU (1) HUP0400323A2 (en)
IL (1) IL158041A0 (en)
IS (1) IS6968A (en)
MX (1) MXPA03008690A (en)
NO (1) NO20034308L (en)
PE (1) PE20021015A1 (en)
PL (1) PL373300A1 (en)
RU (1) RU2003131693A (en)
SK (1) SK12002003A3 (en)
UY (1) UY27234A1 (en)
WO (1) WO2002079192A1 (en)
YU (1) YU84603A (en)
ZA (1) ZA200307466B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
EP1480514A4 (en) 2002-03-01 2008-08-13 Bristol Myers Squibb Co Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
CA2488635C (en) * 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US7361691B2 (en) * 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
EP1590339A4 (en) * 2003-01-28 2007-07-25 Smithkline Beecham Corp Chemical compounds
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
DE102004010207A1 (en) 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
SI1740591T1 (en) 2004-04-02 2009-12-31 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
MX2007007330A (en) * 2004-12-16 2007-10-04 Vertex Pharma Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
US7393667B2 (en) 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
ES2361338T3 (en) 2005-08-29 2011-06-16 Vertex Pharmaceuticals Incorporated PIRID-2-ONAS 3,5-USEFUL DISPOSED AS INHIBITORS OF THE TEC FAMILY OF TIROSINA KINASES NOT LINKED TO RECEIVER.
AU2006284900A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
US7691885B2 (en) 2005-08-29 2010-04-06 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
WO2007026720A1 (en) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Ring-fused pyrazole derivative
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (en) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. Optically active 2-amino-1-(4-fluorophenyl)ethanol
US8063225B2 (en) * 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CL2008001822A1 (en) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compounds derived from thiazolo [5,4-b] pyridine; pharmaceutical composition comprising said compounds; and use of the compound in the treatment of insulin resistance, metabolic syndrome, diabetes, among others.
JP2010531316A (en) * 2007-06-25 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー Benzimidazolamide derivatives as kinase inhibitors
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
AU2009207478B2 (en) * 2008-01-22 2013-11-21 Vernalis (R & D) Ltd Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity
WO2009143051A1 (en) 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Substituted imidazopyr-and imidazotri-azines
CN102388054B (en) 2008-12-19 2015-03-04 西特里斯药业公司 Thiazolopyridine sirtuin modulating compounds
DE102010001064A1 (en) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
ES2453097T3 (en) * 2009-05-27 2014-04-04 Abbvie Inc. Pyrimidine Kinase Activity Inhibitors
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
DK2624696T3 (en) * 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
EP2635566B1 (en) * 2010-11-01 2018-05-16 Boehringer Ingelheim International GmbH Benzimidazole inhibitors of leukotriene production
WO2013056069A1 (en) 2011-10-13 2013-04-18 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
ES2661437T3 (en) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. New substituted bicyclic compounds as bromodomain inhibitors
ES2806135T3 (en) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd New bicyclic bromodomain inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
CN103936719A (en) * 2014-05-14 2014-07-23 中国药科大学 Preparation method and application of benzimidazoles derivatives
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CN107406438B (en) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 Inhibitors of bromodomains
CN107531697A (en) * 2015-04-16 2018-01-02 默克专利股份公司 The ketone derivatives of 3 (base of 1H benzimidazoles 2) 1H pyridines 2
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN117069696B (en) * 2023-08-17 2024-04-26 中国药科大学 A dual-target small molecule inhibitor and its preparation method and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE301651T1 (en) * 1999-06-23 2005-08-15 Aventis Pharma Gmbh SUBSTITUTED BENZIMIDAZOLES
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
JP2004534010A (en) 2004-11-11
BG108206A (en) 2004-11-30
HRP20030844A2 (en) 2005-08-31
WO2002079192A1 (en) 2002-10-10
IS6968A (en) 2003-09-26
CZ20032615A3 (en) 2004-03-17
AR035804A1 (en) 2004-07-14
PE20021015A1 (en) 2002-11-10
SK12002003A3 (en) 2004-10-05
NO20034308D0 (en) 2003-09-26
IL158041A0 (en) 2004-03-28
EP1381598A4 (en) 2008-03-19
MXPA03008690A (en) 2003-12-12
EP1381598A1 (en) 2004-01-21
HUP0400323A2 (en) 2005-11-28
NO20034308L (en) 2003-11-26
BR0208373A (en) 2005-02-22
UY27234A1 (en) 2002-10-31
CN1514833A (en) 2004-07-21
CA2442428A1 (en) 2002-10-10
GEP20053660B (en) 2005-11-10
PL373300A1 (en) 2005-08-22
KR20030083016A (en) 2003-10-23
RU2003131693A (en) 2005-05-10
EE200300475A (en) 2004-02-16
ZA200307466B (en) 2005-01-13

Similar Documents

Publication Publication Date Title
YU84603A (en) Novel tyrosine kinase inhibitors
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
MXPA03010207A (en) Novel 4-anilinoquinoline-3-carboxamides.
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
MXPA05012596A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors.
GB0112348D0 (en) Compounds
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MXPA02005844A (en) Inhibitors of protein kinases.
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
CA2400447A1 (en) Kinase inhibitors
MXPA05005223A (en) Diaminotriazoles useful as inhibitors of protein kinases.
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
ATE371656T1 (en) HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
TW200510380A (en) Mitotic kinesin inhibitors
YU61402A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
MXPA03010961A (en) Thiazole compounds useful as inhibitors of protein kinases.
MXPA03011484A (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
WO2006050109A3 (en) Novel kinase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU3864500A (en) Substituted aza-oxindole derivatives